Published in J Biol Chem on April 16, 2010
Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front Aging Neurosci (2014) 0.94
Type 2 diabetes as a protein misfolding disease. Trends Mol Med (2015) 0.91
Determination of Optimal Sample Size for Quantification of β-Cell Area, Amyloid Area and β-Cell Apoptosis in Isolated Islets. J Histochem Cytochem (2015) 0.91
Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem (2012) 0.82
Degradation of islet amyloid polypeptide by neprilysin. Diabetologia (2012) 0.81
Accumulation of intrahepatic islet amyloid in a nonhuman primate transplant model. Endocrinology (2012) 0.81
Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. Diabetes (2013) 0.79
Overall sulfation of heparan sulfate from pancreatic islet β-TC3 cells increases maximal fibril formation but does not determine binding to the amyloidogenic peptide islet amyloid polypeptide. J Biol Chem (2012) 0.78
Lessons from two prevalent amyloidoses-what amylin and Aβ have in common. Front Aging Neurosci (2013) 0.78
Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro. Endocrinology (2016) 0.75
Proteasome regulates turnover of toxic human amylin in pancreatic cells. Biochem J (2016) 0.75
Matrix Metalloproteinase-9 Protects Islets from Amyloid-induced Toxicity. J Biol Chem (2015) 0.75
Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice. Front Endocrinol (Lausanne) (2016) 0.75
Apoptosis Repressor with Caspase Recruitment Domain Ameliorates Amyloid-Induced β-Cell Apoptosis and JNK Pathway Activation. Diabetes (2017) 0.75
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem (2004) 5.14
Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med (2000) 4.99
Metabolic regulation of brain Abeta by neprilysin. Science (2001) 4.47
Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A (1990) 3.29
Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab (2004) 2.92
Apoptosis participates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology (1997) 2.49
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci (2003) 2.28
Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes (1990) 2.00
Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem (2006) 1.98
Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A (1996) 1.80
Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci (2009) 1.77
Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci (2008) 1.73
Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett (1989) 1.68
Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci U S A (2006) 1.65
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell (2004) 1.57
Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia (2009) 1.55
Degradation of amylin by insulin-degrading enzyme. J Biol Chem (2000) 1.48
Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem (2006) 1.42
Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J Biol Chem (2003) 1.42
Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia (2004) 1.35
Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death. Biochemistry (2008) 1.32
Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides (1995) 1.26
An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes (2003) 1.21
Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes (1994) 1.21
Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res (1989) 1.19
Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res (2002) 1.14
Exercise reverses preamyloid oligomer and prolongs survival in alphaB-crystallin-based desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2007) 1.12
Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis. Diabetes (2007) 1.06
Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res (2008) 1.05
Glucose- and time-dependence of islet amyloid formation in vitro. Biochem Biophys Res Commun (2007) 1.05
Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem (2004) 1.04
The hexosamine biosynthesis pathway regulates insulin secretion via protein glycosylation in mouse islets. Arch Biochem Biophys (2002) 0.99
Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia (1990) 0.98
beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes (2000) 0.96
Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract (1992) 0.94
Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. Biochem J (2002) 0.91
CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood (1996) 0.89
Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia (1994) 0.87
Alternative splicing regulates the endoplasmic reticulum localization or secretion of soluble secreted endopeptidase. J Biol Chem (2001) 0.87
Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab (2004) 0.79
Glucose stimulates and potentiates islet amyloid polypeptide secretion by the B-cell. Horm Metab Res (1991) 0.79
Inhibitors of neprilysin: design, pharmacological and clinical applications. Methods Enzymol (1995) 0.78
Detection of the p110 beta subunit of phosphatidylinositol 3-kinase complexed with neutral endopeptidase. Anticancer Res (2003) 0.78
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature (2006) 15.48
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care (2007) 8.43
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest (2007) 5.38
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol (2010) 4.78
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet (2012) 4.33
Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care (2008) 4.32
Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab (2008) 4.29
Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes (2004) 4.04
Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab (2004) 2.92
Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes (2008) 2.83
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 2.80
Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2006) 2.58
Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med (2004) 2.50
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42
Histone H2B ubiquitylation disrupts local and higher-order chromatin compaction. Nat Chem Biol (2011) 2.39
Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes (2002) 2.30
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry (2005) 2.21
Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes (2011) 2.17
Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care (2003) 2.12
Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care (2003) 2.10
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis (2008) 2.08
Two-dimensional IR spectroscopy and isotope labeling defines the pathway of amyloid formation with residue-specific resolution. Proc Natl Acad Sci U S A (2009) 2.02
Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes (2010) 2.01
Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem (2006) 1.95
Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care (2007) 1.91
Protein folding: defining a "standard" set of experimental conditions and a preliminary kinetic data set of two-state proteins. Protein Sci (2005) 1.91
Peptide models provide evidence for significant structure in the denatured state of a rapidly folding protein: the villin headpiece subdomain. Biochemistry (2004) 1.89
Dynamic NMR line-shape analysis demonstrates that the villin headpiece subdomain folds on the microsecond time scale. J Am Chem Soc (2003) 1.82
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care (2006) 1.78
Minimum waist and visceral fat values for identifying Japanese Americans at risk for the metabolic syndrome. Diabetes Care (2007) 1.78
Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes (2008) 1.78
Insulin response in relation to insulin sensitivity: an appropriate beta-cell response in black South African women. Diabetes Care (2009) 1.78
Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. Arterioscler Thromb Vasc Biol (2003) 1.70
Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem (2004) 1.68
Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care (2002) 1.64
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab (2011) 1.63
The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry (2010) 1.63
The unfolded state of the villin headpiece helical subdomain: computational studies of the role of locally stabilized structure. J Mol Biol (2006) 1.63
The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes (2003) 1.62
A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J Am Chem Soc (2007) 1.59
β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol (2011) 1.59
Effect of modulating unfolded state structure on the folding kinetics of the villin headpiece subdomain. Proc Natl Acad Sci U S A (2005) 1.55
Spectral index for assessment of differential protein expression in shotgun proteomics. J Proteome Res (2008) 1.55
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes (2007) 1.51
Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. J Endocrinol (2005) 1.51
Residue specific resolution of protein folding dynamics using isotope-edited infrared temperature jump spectroscopy. Biochemistry (2007) 1.51
Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes (2003) 1.49
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab (2007) 1.49
A role for helical intermediates in amyloid formation by natively unfolded polypeptides? Phys Biol (2009) 1.49
Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care (2009) 1.48
Characterizing a partially folded intermediate of the villin headpiece domain under non-denaturing conditions: contribution of His41 to the pH-dependent stability of the N-terminal subdomain. J Mol Biol (2005) 1.47
The role of His-18 in amyloid formation by human islet amyloid polypeptide. Biochemistry (2005) 1.46
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care (2007) 1.44
Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab (2010) 1.43
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.41
Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care (2010) 1.40
Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes. Diabetes Care (2007) 1.39
Two-dimensional infrared spectroscopy reveals the complex behaviour of an amyloid fibril inhibitor. Nat Chem (2012) 1.39
Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD. Circ Cardiovasc Genet (2015) 1.38
Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab (2008) 1.38
A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. Protein Eng Des Sel (2009) 1.38
Multistate folding of the villin headpiece domain. J Mol Biol (2005) 1.36
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res (2013) 1.36
Recovery and purification of highly aggregation-prone disulfide-containing peptides: application to islet amyloid polypeptide. Anal Biochem (2005) 1.36
Visceral adiposity and the prevalence of hypertension in Japanese Americans. Circulation (2003) 1.35
Diet-induced weight loss is associated with an improvement in beta-cell function in older men. J Clin Endocrinol Metab (2004) 1.35
Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol (2005) 1.33
Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: implications for mechanistic studies of beta-cell death. Biochemistry (2008) 1.32